Страна: Сінгапур
мова: англійська
Джерело: HSA (Health Sciences Authority)
Rivastigmine (as base)
NOVARTIS (SINGAPORE) PTE LTD
N06DA03
18.00mg/10cm2
PATCH, EXTENDED RELEASE
Rivastigmine (as base) 18.00mg/10cm2
TRANSDERMAL
Prescription Only
LTS Lohmann Therapie-Systeme AG
ACTIVE
2008-04-28
EXELON PATCH Brain-selective cholinesterase inhibitor DESCRIPTION AND COMPOSITION PHARMACEUTICAL FORM Transdermal patch. Each transdermal patch is a thin, matrix-type transdermal patch consisting of three layers. The outside of the backing layer is beige and labelled for each patch as follows: With Exelon Patch 5 and “AMCX” With Exelon Patch 10 and “BHDI” With Exelon Patch 15 and “CNFU”. ACTIVE SUBSTANCE Each Exelon Patch 5 transdermal patch releases 4.6mg of rivastigmine per 24 hours. Each transdermal patch of 5 cm 2 contains 9 mg rivastigmine. Each Exelon Patch 10 transdermal patch releases 9.5mg of rivastigmine per 24 hours. Each transdermal patch of 10 cm 2 contains 18 mg rivastigmine. Each Exelon Patch 15 transdermal patch releases 13.3mg of rivastigmine per 24 hours. Each transdermal patch of 15 cm 2 contains 27 mg rivastigmine. EXCIPIENTS Backing layer: polyethylene terephthalate film, lacquered Medicinal product matrix: alpha-tocopherol, poly (butylmethacrylate, methyl-methacrylate), acrylic copolymer Adhesive matrix: alpha tocopherol, silicone oil, dimethicone Release liner: polyester film, fluoropolymer-coated Novartis Page 2 Country-Specific Package Leaflet 27 May 2014 Exelon Patch INDICATIONS PATCH 5, 10 & 15 Symptomatic treatment of mild to moderately severe, and severe Alzheimer’s dementia. PATCH 5 & 10 Symptomatic treatment of mild to moderate dementia associated with Parkinson’s disease. It is generally recommended to those patients in whom the administration of oral Exelon capsules is unsuitable or infeasible. DOSAGE AND ADMINISTRATION Treatment should be initiated and supervised by a physician experienced Прочитайте повний документ
Exelon Patch Dec 2022.SIN Page 1 of 25 EXELON PATCH Brain-selective cholinesterase inhibitor DESCRIPTION AND COMPOSITION PHARMACEUTICAL FORM Transdermal patch. Each transdermal patch is a thin, matrix-type transdermal patch consisting of three layers. The outside of the backing layer is beige and labelled for each patch as follows: - for Exelon Patch 5; “AMCX” - for Exelon Patch 10; “BHDI” - for Exelon Patch 15; “CNFU”. ACTIVE SUBSTANCE Each Exelon Patch 5 transdermal patch releases 4.6mg of rivastigmine per 24 hours. Each transdermal patch of 5 cm 2 contains 9 mg rivastigmine. Each Exelon Patch 10 transdermal patch releases 9.5mg of rivastigmine per 24 hours. Each transdermal patch of 10 cm 2 contains 18 mg rivastigmine. Each Exelon Patch 15 transdermal patch releases 13.3mg of rivastigmine per 24 hours. Each transdermal patch of 15 cm 2 contains 27 mg rivastigmine. EXCIPIENTS Backing layer: polyethylene terephthalate film, lacquered Medicinal product matrix: alpha-tocopherol, poly (butylmethacrylate, methyl-methacrylate), acrylic copolymer Adhesive matrix: alpha tocopherol, silicone oil, dimethicone Release liner: polyester film, fluoropolymer-coated Exelon Patch Dec 2022.SIN Page 2 of 25 INDICATIONS PATCH 5, 10 & 15 Symptomatic treatment of mild to moderately severe, and severe Alzheimer’s dementia. PATCH 5 & 10 Symptomatic treatment of mild to moderate dementia associated with Parkinson’s disease. It is generally recommended to those patients in whom the administration of oral Exelon capsules is unsuitable or infeasible. DOSAGE REGIMEN AND ADMINISTRATION Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. Diagnosis should be made according to current guidelines. Similar to any treatment initiated in patients with dementia, therapy with rivastigmine should only be started if a caregiver is available to regularly administer and monitor the treatment. POSOLOGY PATCHES RIVASTIGMINE BASE DOSE LOAD RIVASTIGMINE BASE_ _ Прочитайте повний документ